CAMBRIDGE, Mass.--(BUSINESS WIRE)--ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that interim clinical data from the fully enrolled, pivotal PACE trial of its investigational, pan-BCR-ABL inhibitor, ponatinib, will be presented at the 53rd Annual Meeting of the American Society of Hematology (ASH) being held in San Diego, December 10-13, 2011. The interim findings from the PACE trial will be featured in an oral presentation on Sunday, December 11 and also will be highlighted in an investor meeting to be webcast live from San Diego. This trial is being conducted in patients with chronic myeloid leukemia (CML) and Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL) who are resistant or intolerant to either nilotinib or dasatinib, two currently available CML therapies, or those who have the T315I mutation of BCR-ABL for which no current treatments are known to be effective. Thirteen additional abstracts describing clinical and non-clinical work on ponatinib will also be presented at the meeting.
